EPG Online Twitter 
EPG Online Blog 
Disease Knowledge Drug Updates
- ACCOLATE
- Benlysta 120 mg
- Protopic 0.1% ointment
- Aminophylline injection BP 500 mg/2 ml
- Gastrocote Liquid
- Equasym XL 10 mg, 20 mg or 30 mg Capsules
- Tazocin 2g/0.25g and 4g/0.5g Powder for Solution for Injection or Infusion
- Imodium Plus Caplets GSL
- Ilaris 150mg powder for solution for injection
- Voltarol 25mg, 50mg Rapid Tablets
- E45 Itch Relief Cream
- Lescol XL 80 mg Prolonged Release Tablets
- Onbrez Breezhaler 300 microgram inhalation powder, hard capsules
- Heparin calcium 25,000 I.U./ml Solution for injection or concentrate for solution for infusion
- Kamillosan Ointment
- Hyoscine Hydrobromide 400 micrograms/ml Solution for Injection
- Abilify Tablets, Orodispersible Tablets, Oral Solution (Otsuka & Bristol-Myers Squibb)
- Anugesic HC Cream
- Arimidex 1mg Film-Coated Tablet
- Avodart 0.5mg soft capsules
- Gabapentin 100 mg Capsules
- Dovonex Ointment
- Premique Low Dose 0.3mg/1.5mg Modified Release Tablets
- Premique 0.625mg/5mg Coated Tablets
- Innohep 20,000 IU/ml and Innohep syringe 20,000 IU/ml
- NovoRapid 100 U/ml in a vial, NovoRapid Penfill 100 U/ml, NovoRapid FlexPen 100 U/ml, NovoRapid FlexTouch 100 U/ml
- Accupro Tablets 5mg, 10mg, 20mg & 40mg
- Acular
- Betaferon
- Cimzia 200 mg solution for injection
- Olanzapine 2.5mg Film-coated Tablets
- Pentasa Slow Release Tablets 1g
- COZAAR 2.5 mg/ml powder and solvent for oral suspension
- Daktarin Gold 2% Cream
- Edronax 4mg Tablets
- COZAAR 12.5 mg, 25 mg, 50 mg and 100 mg Film-Coated Tablets
- Tobi 300 mg/5 ml Nebuliser Solution
- Elocon Cream
- Famciclovir 125 mg Tablets
- Famciclovir 250mg Tablets
Renal Cell Carcinoma
Please note - The EPG Renal Cell Carcinoma Knowledge Centre is for Doctors and other Healthcare Professionals. Enter the Renal Cell Carcinoma Knowledge Centre.
Kidney cancer is the 14th most common cancer and there were approximately 200,000 new kidney cancer cases worldwide in 2002. RCC is a global problem, but its incidence varies considerably by geographical location. Rates of RCC are high in North America, Europe and Australia, whereas rates are low in Africa, India and China. Until recently, the worldwide incidence of RCC has increased by approximately 2% every year..
It is estimated that there will be 54,390 new cases of kidney cancer and 13,010 kidney cancer-related deaths in the US in 2008 alone. Global incidence data on mRCC are lacking, but can be estimated from figures for overall RCC rates.
In 2006, there were estimated to be 63,300 new cases of kidney cancer (tenth most common cancer in the European Union [EU]7) and 26,400 kidney cancer-related deaths in the EU. Kidney cancer incidence in specific European countries is shown in Figure 1.2. The Czech Republic, Estonia and Iceland have the highest RCC rates in Europe. Although the worldwide incidence of RCC is thought to be increasing,5 data from a recent European study, which analysed kidney cancer incidence in 1980– 2004, indicate a shift towards stabilization or a decrease in incidence in recent years in both sexes. Recently, kidney cancer incidence rates also have decreased or stabilized in some countries in Northern Europe, except for England, Scotland and Ireland, whereas incidence in Eastern Europe has generally increased (except for women in the early 2000s). The highest sustained decreases in incidence rates were seen in Sweden; declines were observed in both sexes throughout the 25-year study period.
Enter the Renal Cell Carcinoma Knowledge Centre
What’s in the Renal Cell Carcinoma Knowledge Centre?
- NEXAVAR Film-Coated Tablets
Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable ... - SUTENT Hard Capsules
... of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance. Metastatic Renal Cell Carcinoma (MRCC) SUTENT is indicated for the treatment of advanced and/ormetastatic renal cell carcinoma (MRCC ... - Votrient 200 mg film-coated tablets
Votrient is indicated for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease ... - Votrient 200 mg film-coated tablets
Votrient is indicated for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease ... - Votrient 200 mg and 400 mg film coated tablets
... nbsp;Votrient is indicated for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. ... - VELBE
... drugs for the treatment of: Hodgkin's disease; non-Hodgkin's lymphoma; carcinoma of the breast; methotrexate-resistant choriocarcinoma; renal cell carcinoma; testicular teratoma and seminoma; histiocytosis X. Other neoplasms occasionally show a marked response to Velbe, but less frequently than the ...
